Table I.
Demographic characteristics of the 20 adult study subjects
| Characteristic | Value |
|---|---|
| Median Age at seroconversion (range) | 24 (20–46) |
| Race | |
| Caucasian | 100% |
| Other | 0% |
| % Male | 60% |
| Genotype | |
| 1a | 16 |
| 1b | 1 |
| 2b | 1 |
| 3a | 1 |
| Unknowna | 1 |
| Outcome of infection (%) | |
| Persistent | 14 (70) |
| Control | 4 (20) |
| Unknownb | 2 (10) |
| Mode of infection injection drug use (%)c | 19 (95) |
| Mean length of follow-up | 673 days (106–1521) |
| Mean number of time points studied | 3.5 (1–6) |
| HCV RNA levels during the first 180 days following | Median 95,700 IU/ml |
| infection | (0 – 6.66 × 106 IU/ml) |
| HCV RNA levels after more than 180 days following | Median 47,300 IU/ml |
| infection | (0 –7.56 × 106 IU/ml) |
| Mean number of epitopes tested per patient | 2.5 (1–5) |
a
For one subject who cleared HCV viremia rapidly and missed a monthly visit, HCV antibody seroconversion but no period of viremia was observed. Therefore, the genotype of that subject’s infection is unknown.
b
Two subjects were lost to follow-up before 300 days following infection, the minimum time of follow-up required to meet the definition of any outcome.
c
The only study subject not infected via injection drug use was infected in a common source outbreak.